Cargando…
P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429383/ http://dx.doi.org/10.1097/01.HS9.0000969120.99711.2b |
| _version_ | 1785090698820714496 |
|---|---|
| author | Minetto, Paola Guolo, Fabio Rosellini, Sara Piciocchi, Alfonso Marconi, Giovanni Audisio, Ernesta Priolo, Giorgio Papayannidis, Cristina Martelli, Maurizio Paoloni, Francesca Bocchia, Monica Lanza, Francesco Lico, Albana Ciceri, Fabio Giovanni Della Porta, Matteo Frigeni, Marco Giaccone, Luisa Beltrami, Germana Borlenghi, Erika Chiara DI Chio, Maria Selleri, Carmine Crea, Enrico Urbino, Irene Sartor, Chiara Minotti, Clara Arena, Valentina Nanni, Jacopo Simonetti, Giorgia Teresa Bochicchio, Maria Saglio, Giuseppe Venditti, Adrianno Vignetti, Marco Fazi, Paola Tedone, Elisabetta Martinelli, Giovanni Massimo Lemoli, Roberto |
| author_facet | Minetto, Paola Guolo, Fabio Rosellini, Sara Piciocchi, Alfonso Marconi, Giovanni Audisio, Ernesta Priolo, Giorgio Papayannidis, Cristina Martelli, Maurizio Paoloni, Francesca Bocchia, Monica Lanza, Francesco Lico, Albana Ciceri, Fabio Giovanni Della Porta, Matteo Frigeni, Marco Giaccone, Luisa Beltrami, Germana Borlenghi, Erika Chiara DI Chio, Maria Selleri, Carmine Crea, Enrico Urbino, Irene Sartor, Chiara Minotti, Clara Arena, Valentina Nanni, Jacopo Simonetti, Giorgia Teresa Bochicchio, Maria Saglio, Giuseppe Venditti, Adrianno Vignetti, Marco Fazi, Paola Tedone, Elisabetta Martinelli, Giovanni Massimo Lemoli, Roberto |
| author_sort | Minetto, Paola |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429383 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104293832023-08-17 P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML Minetto, Paola Guolo, Fabio Rosellini, Sara Piciocchi, Alfonso Marconi, Giovanni Audisio, Ernesta Priolo, Giorgio Papayannidis, Cristina Martelli, Maurizio Paoloni, Francesca Bocchia, Monica Lanza, Francesco Lico, Albana Ciceri, Fabio Giovanni Della Porta, Matteo Frigeni, Marco Giaccone, Luisa Beltrami, Germana Borlenghi, Erika Chiara DI Chio, Maria Selleri, Carmine Crea, Enrico Urbino, Irene Sartor, Chiara Minotti, Clara Arena, Valentina Nanni, Jacopo Simonetti, Giorgia Teresa Bochicchio, Maria Saglio, Giuseppe Venditti, Adrianno Vignetti, Marco Fazi, Paola Tedone, Elisabetta Martinelli, Giovanni Massimo Lemoli, Roberto Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429383/ http://dx.doi.org/10.1097/01.HS9.0000969120.99711.2b Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Minetto, Paola Guolo, Fabio Rosellini, Sara Piciocchi, Alfonso Marconi, Giovanni Audisio, Ernesta Priolo, Giorgio Papayannidis, Cristina Martelli, Maurizio Paoloni, Francesca Bocchia, Monica Lanza, Francesco Lico, Albana Ciceri, Fabio Giovanni Della Porta, Matteo Frigeni, Marco Giaccone, Luisa Beltrami, Germana Borlenghi, Erika Chiara DI Chio, Maria Selleri, Carmine Crea, Enrico Urbino, Irene Sartor, Chiara Minotti, Clara Arena, Valentina Nanni, Jacopo Simonetti, Giorgia Teresa Bochicchio, Maria Saglio, Giuseppe Venditti, Adrianno Vignetti, Marco Fazi, Paola Tedone, Elisabetta Martinelli, Giovanni Massimo Lemoli, Roberto P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML |
| title | P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML |
| title_full | P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML |
| title_fullStr | P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML |
| title_full_unstemmed | P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML |
| title_short | P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML |
| title_sort | p553: preliminary results of mrd analysis of aml1718, a phase 2 open-label study of venetoclax, fludarabine, idarubicin and cytarabine (v-flai) in the induction therapy of non low-risk aml |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429383/ http://dx.doi.org/10.1097/01.HS9.0000969120.99711.2b |
| work_keys_str_mv | AT minettopaola p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT guolofabio p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT rosellinisara p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT piciocchialfonso p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT marconigiovanni p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT audisioernesta p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT priologiorgio p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT papayannidiscristina p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT martellimaurizio p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT paolonifrancesca p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT bocchiamonica p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT lanzafrancesco p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT licoalbana p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT cicerifabio p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT giovannidellaportamatteo p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT frigenimarco p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT giacconeluisa p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT beltramigermana p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT borlenghierika p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT chiaradichiomaria p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT sellericarmine p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT creaenrico p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT urbinoirene p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT sartorchiara p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT minotticlara p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT arenavalentina p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT nannijacopo p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT simonettigiorgia p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT teresabochicchiomaria p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT sagliogiuseppe p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT vendittiadrianno p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT vignettimarco p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT fazipaola p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT tedoneelisabetta p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT martinelligiovanni p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml AT massimolemoliroberto p553preliminaryresultsofmrdanalysisofaml1718aphase2openlabelstudyofvenetoclaxfludarabineidarubicinandcytarabinevflaiintheinductiontherapyofnonlowriskaml |